missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CXCL9 (MIG) Monoclonal Antibody (C7), Invitrogen™
Description
MIG, also known as CXCL9, is a T-cell chemoattractant inducible by gamma interferon that is a member of the CXC chemokine family of cytokines.This gene is mapped to 4q21. It is noted that, although the best-described activities of the chemokines are as chemotactic factors, chemokines also have an effect on T-cell activation, angiogenesis, and HIV infection. While most CXC chemokines are chemotactic for neutrophils, MIG and INP10 are unusual and similar in being CXC chemokines that are chemotactic for lymphocytes and inactive in neutrophils.
Spécification
Spécification
| Antígeno | CXCL9 (MIG) |
| Aplicaciones | Immunohistochemistry (Paraffin), Western Blot |
| Clasificación | Monoclonal |
| Clon | C7 |
| Concentración | 1 mg/mL |
| Conjugado | Unconjugated |
| Formulación | PBS with 50% glycerol and 0.05% ProClin 300; pH 7.4 |
| génica | CXCL9 |
| N.º de referencia del gen | Q07325 |
| Alias de gen | BB139920; C Cmotif chemokine; C X C motif chemokine; CC motif chemokine; CCmotif chemokine; chemokine (C-X-C motif) ligand 9; CMK; crg-10; CXC; CXC motif chemokine; C-X-C motif chemokine 9; C-X-C motif chemokine ligand 9; CXCL; CXCL9; gamma interferon-induced monokine; gamma-interferon-induced monokine; HuMIG; M119; Mig; monokine induced by gamma interferon; monokine induced by interferon gamma; monokine induced by interferon-gamma; MuMIG; protein m119; SCYB9; small inducible cytokine B subfamily (Cys-X-Cys), member 9; small inducible cytokine B9; small-inducible cytokine B9 |
| Afficher plus |
Nom du produit
En cliquant sur Soumettre, vous reconnaissez que vous pouvez être contacté par Fisher Scientific au sujet des informations que vous avez fournies dans ce formulaire. Nous ne partagerons pas vos informations à d'autres fins. Toutes les informations de contact fournies seront également conservées conformément à notre politique de confidentialité. Politique de confidentialité.
Vous avez repéré une opportunité d'amélioration ?